...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: What's going on with the Phase 2 ZEN-3694 mCRPC trial?

I wonder does this mean that full results would be available for presentation or that they will have completed the treatment phase with analysis to follow? Since it is an open label trial (not blinded) they have had the data on an ongoing basis so it would be great if there is a full analysis ready for presentation at a conference by Oct 2019.

I also wonder what happens with the 3 super star patients and other patients that are doing well after the trial ends?

Toinv

Share
New Message
Please login to post a reply